MiNK Therapeutics (INKT) Competitors $15.36 -0.47 (-2.97%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$15.66 +0.30 (+1.92%) As of 09/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. MNPR, AVIR, ENGN, PRQR, ALLO, JBIO, PBYI, FENC, DBVT, and VORShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Monopar Therapeutics (MNPR), Atea Pharmaceuticals (AVIR), enGene (ENGN), ProQR Therapeutics (PRQR), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Puma Biotechnology (PBYI), Adherex Technologies (FENC), DBV Technologies (DBVT), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Monopar Therapeutics Atea Pharmaceuticals enGene ProQR Therapeutics Allogene Therapeutics Jade Biosciences Puma Biotechnology Adherex Technologies DBV Technologies Vor Biopharma Monopar Therapeutics (NASDAQ:MNPR) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Does the media prefer MNPR or INKT? In the previous week, Monopar Therapeutics had 15 more articles in the media than MiNK Therapeutics. MarketBeat recorded 15 mentions for Monopar Therapeutics and 0 mentions for MiNK Therapeutics. Monopar Therapeutics' average media sentiment score of 0.50 beat MiNK Therapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Monopar Therapeutics Neutral MiNK Therapeutics Neutral Which has higher earnings and valuation, MNPR or INKT? Monopar Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.33-13.49MiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.33 Which has more volatility & risk, MNPR or INKT? Monopar Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Do institutionals & insiders hold more shares of MNPR or INKT? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MNPR or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -41.76% -39.49% MiNK Therapeutics N/A N/A -227.24% Do analysts recommend MNPR or INKT? Monopar Therapeutics presently has a consensus price target of $71.75, suggesting a potential upside of 59.69%. MiNK Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 144.14%. Given MiNK Therapeutics' higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryMiNK Therapeutics beats Monopar Therapeutics on 7 of the 13 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.60M$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.53%P/E Ratio-5.3321.3475.6926.28Price / SalesN/A471.32544.78188.18Price / CashN/A45.5837.2059.76Price / Book-3.1110.0511.506.41Net Income-$9.51M-$53.33M$3.28B$270.56M7 Day Performance9.17%1.39%1.42%3.13%1 Month Performance27.36%11.91%11.28%9.74%1 Year Performance95.77%13.21%59.03%28.17% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.2209 of 5 stars$15.36-3.0%$37.50+144.1%+92.5%$71.60MN/A-5.3330Negative NewsGap DownMNPRMonopar Therapeutics3.1131 of 5 stars$43.44+11.8%$69.57+60.2%+1,726.4%$267.90MN/A-13.0410Analyst ForecastAVIRAtea Pharmaceuticals2.1736 of 5 stars$3.35+0.7%$6.00+78.9%-13.9%$265.86MN/A-2.0870News CoveragePositive NewsENGNenGene2.7271 of 5 stars$5.21+4.1%$23.29+347.4%-15.7%$264.95MN/A-3.1431Analyst ForecastGap DownPRQRProQR Therapeutics3.0119 of 5 stars$2.45+2.3%$8.00+227.2%+26.6%$258.19M$20.46M-5.33180News CoverageALLOAllogene Therapeutics2.8079 of 5 stars$1.16+4.1%$8.44+631.1%-54.0%$256.27M$20K-1.04310JBIOJade Biosciences2.7814 of 5 stars$7.83+0.6%$16.00+104.3%N/A$255.49MN/A-0.2620PBYIPuma Biotechnology4.1105 of 5 stars$5.04-1.5%$7.00+39.0%+103.0%$253.36M$230.50M5.13200FENCAdherex Technologies1.6221 of 5 stars$8.98-2.2%$13.33+48.5%+75.6%$250.74M$47.54M-21.4710DBVTDBV Technologies2.8684 of 5 stars$9.15-0.7%$14.75+61.2%+141.0%$250.65M$4.15M-1.9280VORVor Biopharma2.155 of 5 stars$1.97+1.8%$6.07+208.7%+84.4%$248.93MN/A-1.19140 Related Companies and Tools Related Companies Monopar Therapeutics Competitors Atea Pharmaceuticals Competitors enGene Competitors ProQR Therapeutics Competitors Allogene Therapeutics Competitors Jade Biosciences Competitors Puma Biotechnology Competitors Adherex Technologies Competitors DBV Technologies Competitors Vor Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts